Efficacy of BIO-K+ CL1285® Prophylaxis in the Prevention of Traveler's Diarrhea in Adults
This study has been completed.
Sponsor:
Bio-K Plus International Inc.
Collaborator:
ethica Clinical Research Inc.
Information provided by:
Bio-K Plus International Inc.
ClinicalTrials.gov Identifier:
NCT00737412
First received: August 15, 2008
Last updated: January 19, 2010
Last verified: January 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine the efficacy of Bio-K+ CL1285 in reducing traveler's diarrhea.
| Condition | Intervention | Phase |
|---|---|---|
|
Diarrhea |
Other: Probiotic: Bio-K+ CL1285 Other: Placebo |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Prevention |
| Official Title: | A Double-blind, Randomized, Placebo Controlled, Multicenter Study of the Efficacy of BIO-K+ CL1285® Prophylaxis in the Prevention of Traveler's Diarrhea in Adults. |
Resource links provided by NLM:
MedlinePlus related topics:
Diarrhea
Drug Information available for:
Lactobacillus
U.S. FDA Resources
Further study details as provided by Bio-K Plus International Inc.:
Primary Outcome Measures:
- To determine the efficacy of Bio-K+ CL1285 RX® in reducing traveler's diarrhea by comparing the incidence of diarrhea in travelers during their stay abroad and upon their return to Canada, following either BIO-K+CL1285 RX® or placebo prophylaxis. [ Time Frame: March 2008 to April 2009 ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- To compare the severity of diarrhea in travelers during their stay abroad and upon their return to Canada, following either BIO-K+CL1285 RX® or placebo prophylaxis. [ Time Frame: March 2008 to April 2009 ] [ Designated as safety issue: No ]
- To compare the safety profile of BIO-K+CL1285 RX® to that of placebo [ Time Frame: March 2008 to April 2009 ] [ Designated as safety issue: Yes ]
- To compare the physician and traveler satisfaction following daily prophylaxis with either BIO-K+CL1285 RX® or placebo [ Time Frame: March 08 to April 09 ] [ Designated as safety issue: No ]
- To evaluate and compare the health economic impact of daily prophylaxis with BIO-K+CL1285 RX®. [ Time Frame: March 08 to April 09 ] [ Designated as safety issue: No ]
| Enrollment: | 277 |
| Study Start Date: | April 2008 |
| Study Completion Date: | January 2010 |
| Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: 1
The probiotic Bio-K+ CL1285 RX®
|
Other: Probiotic: Bio-K+ CL1285
The probiotic Bio-K+ CL1285 RX®, a mixture of Lactobacillus acidophilus and Lactobacillus casei, contains over 50 billion living bacteria per administered dose.
Other Name: Bio-K+ CL1285 RX®
|
|
Placebo Comparator: 2
Placebo
|
Other: Placebo
Matching capsules devoid of microorganisms
Other Name: Placebo
|
Detailed Description:
Determine efficacy of Bio-K+ CL1285 in reducing Traveler's Diarrhea by comparing the incidence of diarrhea in travelers during their stay abroad and upon their return to Canada following either Bio-K+ CL-1285 OR placebo prophylaxis.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Male or female subjects over 18 years of age traveling to Mexico, Central America, South America and Caribbean Islands as direct destinations or on cruises to the same destinations.
- The trips last a minimum of 7 days and a maximum of 21 days.
- Women of child bearing capacity who are not pregnant at the moment of screening (pregnancy test done on-site) and agree to use an acceptable form of birth control for the duration of the study (e.g. Condom, oral contraceptives, etc.) are allowed to participate.
Exclusion Criteria:
- active diarrhea;
- pregnancy; breastfeeding
- 3 diarrheic episodes within 24 hours in the 15 days preceding the date of the departure;
- antibiotic treatment during the last 15 days or ongoing treatment at the time of departure;
- consumption of fermented milk, yogourt or probiotics probiotics in the 15 days preceding the date of the departure;
- immunosuppressed state or any health condition being susceptible to decompensate during the study (including malignant hemo-pathologies, AIDS, bone marrow transplant or organ transplant).
- active radiotherapy or chemotherapy as cancer treatment
- the administration of an ETEC/cholera vaccine or any other diarrhea vaccine in the three months prior to study initiation
- an active, non-controlled intestinal disease;
- ileostomy, jejunostomy or colostomy
- concomitant participation in another clinical trial
- mental or other conditions, or language barriers rendering the subject unable to understand the nature, scope, and possible consequences of the study or complete the self-administered questionnaires;
- subject unlikely to comply with protocol, e.g., uncooperative attitude, and unlikelihood of completing the study,
- allergies to any ingredients in the study product (active product or placebo)
- current use of illicit drug and alcohol abuse
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00737412
Locations
| Canada, Quebec | |
| Clinique Santé Voyage des Prairies | |
| Joliette, Quebec, Canada, J6E 1G2 | |
| Clinique Santé Voyage de Laval | |
| Laval, Quebec, Canada, H7G2E6 | |
| Sant Voyage Medisys | |
| Montreal, Quebec, Canada, H3A 3C6 | |
| Clinique Santé Voyage Saint-Luc | |
| Montreal, Quebec, Canada, H2X 2H9 | |
Sponsors and Collaborators
Bio-K Plus International Inc.
ethica Clinical Research Inc.
Investigators
| Principal Investigator: | Dominique Tessier, MD | Sante Voyage Medisys |
| Principal Investigator: | Benoit Brizard, MD | Clinique Santé Voyage de Laval |
| Principal Investigator: | Benoit Cote, MD | Clinique Sante Voyage des Prairies |
| Principal Investigator: | Jean Vincelette, MD | Sante Voyage Saint-Luc |
More Information
No publications provided
| Responsible Party: | Marcia T. Ruiz, Bio-K+ International Inc. |
| ClinicalTrials.gov Identifier: | NCT00737412 History of Changes |
| Other Study ID Numbers: | CL1285-TD-M02 |
| Study First Received: | August 15, 2008 |
| Last Updated: | January 19, 2010 |
| Health Authority: | Canada: Health Canada |
Keywords provided by Bio-K Plus International Inc.:
|
Bio-K+CL1285 Probiotics Traveler's Diarrhea Lactobacillus Acidophilus Lactobacillus Casei |
Additional relevant MeSH terms:
|
Diarrhea Dysentery Signs and Symptoms, Digestive Signs and Symptoms |
Gastroenteritis Gastrointestinal Diseases Digestive System Diseases Intestinal Diseases |
ClinicalTrials.gov processed this record on June 17, 2013